Live Breaking News & Updates on ஓலேஃப் க்ரோ

 E-Mail
With the Proof of Concept funding line, the ERC grants recipients of ERC frontier research funds (Starting, Consolidator, Advanced or Synergy grants) with 150.000 Euro to develop promising ideas with commercial or societal potential to the proof of concept stage. With this funding, Olaf Groß and his team in the Metabolism and Inflammation Group at the Institute of Neuropathology of the Medical Center - University of Freiburg will test whether a new class of immune activating drugs they discovered can boost the effectiveness of cancer immunotherapies or vaccines against infectious diseases.
Groß studies a protein complex called the inflammasome within macrophages, specialized cells of the body s defense system that patrol tissues for signs of danger. When their inflammasome is activated, macrophages sound the alarm by releasing of potent factors called cytokines. These cytokines alert other cells in the body, initiating an inflammatory response that helps other ....

Technical University Of Munich , University Of Freiburg , Institute Of Neuropathology The Medical Center , University Of Lausanne , Centre For Integrative Biological Signalling , Inflammation Group , Olaf Gro , Medical Center , Technical University , University Medical , Emerging Field , Metabolism Research , Integrative Biological Signalling , Medicine Health , தொழில்நுட்ப பல்கலைக்கழகம் ஆஃப் முனிச் , ஓலேஃப் க்ரோ , மருத்துவ மையம் , தொழில்நுட்ப பல்கலைக்கழகம் , பல்கலைக்கழகம் மருத்துவ , வளர்ந்து வருகிறது புலம் , வளர்சிதை மாற்றம் ஆராய்ச்சி , மருந்து ஆரோக்கியம் ,